What is NDC 65862-025?

65862-025 is the product NDC for Lamivudine, Lamivudine 150 mg/1 tablet, film coated, listed with the FDA by Aurobindo Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.

Aurobindo Pharma Limited, NDC labeler code 65862. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lamivudine?

24 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lamivudine NDC 65862-025 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)65862-025Labeler and product segments. Claims need a package NDC.

Product NDC at billing width65862-0025Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
65862-025-10	65862002510	6 BLISTER PACK in 1 CARTON (65862-025-10) / 10 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Nov 21, 2016
65862-025-60	65862002560	60 TABLET, FILM COATED in 1 BOTTLE (65862-025-60)Marketed from Nov 21, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Aurobindo Pharma LimitedNDC labeler code 65862
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077464
Marketing start: Nov 21, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 65862-025_0c6a0ca4-d63c-4018-909a-d9e7a2821ed4SPL ID 0c6a0ca4-d63c-4018-909a-d9e7a2821ed4SPL set ID a8a492ab-396a-4b7c-99b3-bcb6d3386f71RxCUI 199147, 349491UNII 2T8Q726O95
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N465862002510 followed by a unit qualifier and the quantity

Package 65862-0025-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 29, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. Lamivudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 65862-025

What is NDC 65862-025?: 65862-025 is the product NDC for Lamivudine, Lamivudine 150 mg/1 tablet, film coated, listed with the FDA by Aurobindo Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lamivudine.
What is the active ingredient?: Lamivudine.
Who is the labeler?: Aurobindo Pharma Limited, NDC labeler code 65862. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lamivudine?: 24 other product NDCs are listed under this name. See all Lamivudine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Lamivudine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-1459	67046-1459-03
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	American Health Packaging	60687-720	60687-0720-21
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-001	33342-0001-09
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-002	33342-0002-07
lamivudine	Lamivudine 100 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-001	31722-0001-0231722-0001-60
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-710	64380-0710-03
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-711	64380-0711-04
Lamivudine	Lamivudine 150 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-623	50742-0623-60
Lamivudine	Lamivudine 300 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-624	50742-0624-60
Lamivudine	Lamivudine 10 mg/mL	SolutionOral	Rising Pharma Holdings, Inc.	57237-274	57237-0274-24

All 25 Lamivudine NDCs